Results 161 to 170 of about 55,598 (274)

Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale

open access: yesGeriatrics &Gerontology International, Volume 26, Issue 1, January 2026.
ABSTRACT The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy.
Masaki Mogi   +4 more
wiley   +1 more source

Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial. [PDF]

open access: yesMedicine (Baltimore), 2023
Seo SY   +18 more
europepmc   +1 more source

Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial

open access: yesHelicobacter, Volume 31, Issue 1, January/February 2026.
ABSTRACT Background Tegoprazan, a potassium‐competitive acid blocker, offers potent and sustained acid inhibition and potentially improves eradication efficacy. Aim This study aimed to evaluate the efficacy and safety of tegoprazan‐based triple therapy with two dosing regimens compared with that of lansoprazole‐based therapy for first‐line Helicobacter
Jae Yong Park   +19 more
wiley   +1 more source

What shapes local alcohol, narcotics, and tobacco policy in Sweden?

open access: yesInternational Journal of Social Welfare, Volume 35, Issue 1, January 2026.
Abstract Swedish municipalities vary significantly in their commitment to preventing alcohol, narcotics, and tobacco related (ANT) problems. This study investigates the drivers of local policy development, focusing on the salience of ANT‐related problems, municipal economic resources, and the political orientation of local governments.
Thor Norström   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy